Theravance Biopharma Inc
NASDAQ:TBPH
Theravance Biopharma Inc
NASDAQ:TBPH
Price:
9.38 USD
-0.95%
Market Closed
Updated:
May 12, 2024
P/E
Price to Earnings
Price to Earnings
-8.2
Current
-4
Median
23.4
Industry
Lower
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-8.2
Market Cap
/
451.1m
Net Income
-55.2m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| KY |
|
Theravance Biopharma Inc
NASDAQ:TBPH
|
451.1m USD | -8.2 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 347 888.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.3B USD | 117.7 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 44.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | -15 783.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.8B USD | 9.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
329.4B USD | 142.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
191.8B GBP | 37.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
180.6B CHF | 11.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
179.5B CHF | 15.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.1B USD | -511.8 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-14.1
2-Years Forward
P/E
-28
3-Years Forward
P/E
7.2
You don't have any saved screeners yet
